Rigel Pharmaceuticals (NASDAQ:RIGL) is set to give its latest quarterly earnings report on Tuesday, 2026-03-03. Here's what investors need to know before the announcement.

Analysts estimate that Rigel Pharmaceuticals will report an earnings per share (EPS) of $1.25.

Anticipation surrounds Rigel Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.

New investors should understand that while earnings performance is important, market reactions are often driven by guidance.

Past Earnings Performance

During the last quarter, the company reported an EPS beat by $0.61, leading to a 33.37% increase in the share price on the subsequent day.

Here's a look at Rigel Pharmaceuticals's past performance and the resulting price change:

Quarter	Q3 2025	Q2 2025	Q1 2025	Q4 2024
EPS Estimate	0.85	1.63	0.09	0.55
EPS Actual	1.46	3.28	0.63	0.80
Price Change %	33.37	22.98	1.15	-8.11

Market Performance of Rigel Pharmaceuticals's Stock

Shares of Rigel Pharmaceuticals were trading at $34.74 as of February 27. Over the last 52-week period, shares are up 56.7%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

Get to Know Rigel Pharmaceuticals Better

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Breaking Down Rigel Pharmaceuticals's Financial Performance

Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.

Revenue Growth: Rigel Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately 25.59%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: Rigel Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 40.17% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 27.96%, the company showcases effective utilization of equity capital.

Return on Assets (ROA): Rigel Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 12.42%, the company showcases efficient use of assets and strong financial health.

Debt Management: Rigel Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.52, reflecting a lower dependency on debt financing and a more conservative financial approach.

To track all earnings releases for Rigel Pharmaceuticals visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.